Hims & Hers Health, Inc. (HIMS) closed at $29.76 in the latest trading session, marking a -4.03% move from the prior day. This change lagged the S&P 500's daily loss of 0.64%. At the same time, the ...

Telemedicine company Hims & Hers Health has been one of the hottest healthcare stocks in recent memory. Changes at UnitedHealth Group have attracted the attention of investors, but a smaller player ...

In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $41.98, marking a -34.63% move from the previous day. This move lagged the S&P 500's daily gain of 0.96%. Meanwhile, the Dow ...

The market expects Hims & Hers Health, Inc. (HIMS) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2026. This widely-known ...

Hims & Hers remains a compelling long-term play, with a resilient subscription-driven model, 85%+ retention, and 2.4 million users fueling growth. Despite the Novo Nordisk partnership loss, Hims ...

Hims & Hers Health (HIMS) said in a 10-K filing that it received a letter from the staff of the Securities and Exchange Commission’s Division of Enforcement in February notifying the company of an ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. WASHINGTON (AP) — For the first time, ...

The MarketWatch News Department was not involved in the creation of this content. Eucalyptus is a consumer healthcare leader in Australia, the UK and Germany, with expanding new operations in Japan ...

Hims is a telehealth company offering discreet virtual consultations and prescription delivery for men's health concerns. Hims' hair loss program uses FDA-approved treatments like finasteride and ...

Read full article: Georgia attorney general warns of price gouging, scams amid massive Southeast Georgia wildfire Read full article: ‘My heart felt like it dropped’: Brantley County wildfire destroyed ...